Trial intelligence / Profile preview

MA09-hRPE in Advanced Dry AMD

NCT01344993Phase 2Completed

Sponsor
Astellas Institute for Regenerative Medicine
Start
Jun 2011
Primary completion
Aug 2015
Modality
Patient-derived iPSCs, Allogeneic iPSCs
Countries
1
01

Overview

A Phase 2 trial of ASP7317 in age-related macular degeneration (AMD), sponsored by Astellas Institute for Regenerative Medicine. Started Jun 2011; status: completed.

02

Drugs

ASP7317
03

Conditions

age-related macular degeneration (AMD)

Beyond the preview

Go deeper on NCT01344993.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01344993.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call